ICRM
VRTX icon

Insight Capital Research & Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Insight Capital Research & Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,209
Closed -$86K – 169
2013
Q3 		$86K Sell
1,209
-5,396
-82% -$429K 0.02% 165
2013
Q2 		$529K Buy
+6,605
New +$486K 0.14% 150

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Insight Capital Research & Management's VRTX Position: Q4 2013 in Review

Insight Capital Research & Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2013, closing a stake of 1,209 shares — an estimated $86K sold.

Insight Capital Research & Management first reported a position in VRTX in Q2 2013 and held it in 2 quarters. The position peaked at $529K in Q2 2013. 387 funds tracked by Wall St. Rank hold VRTX as of Q4 2013.

  • Insight Capital Research & Management reported no remaining Vertex Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Insight Capital Research & Management sold 1,209 Vertex Pharmaceuticals shares in Q4 2013, an estimated $86K.
  • Insight Capital Research & Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Insight Capital Research & Management's Vertex Pharmaceuticals position peaked at $529K in Q2 2013.
  • 387 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2013.

Based on Insight Capital Research & Management's 13F filing for Q4 2013, filed 12 Feb 2014.